|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 983.14 USD | -2.04% |
|
-4.28% | -8.97% |
| 01:17am | Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial | DJ |
| 12:31am | Roche, Zealand's obesity drug shows up to 10.7% weight loss in mid-stage trial | RE |
Business description: Eli Lilly and Company
- endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (14.4%);
- immunology diseases (8.1%);
- neurology (2.1%): primarily drugs used in treating depression and schizophrenia;
- other (1.4%).
Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Number of employees: 50,000
Sales by Activity: Eli Lilly and Company
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Discovery, Dev., Manufacturing, Marketing, and Sales of Pharmaceutical Products | 2.83TCr | 2.85TCr | 3.41TCr | 4.5TCr | 6.52TCr |
Geographical breakdown of sales: Eli Lilly and Company
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States (U.S.) | 1.68TCr | 1.82TCr | 2.18TCr | 3.04TCr | 4.35TCr |
Europe | 477.68Cr | 429.92Cr | 617.47Cr | 692.07Cr | 1.16TCr |
Rest of world | 270.22Cr | 285.2Cr | 294.62Cr | 427.14Cr | 605.7Cr |
Japan | 236.7Cr | 174.73Cr | 167.26Cr | 181.49Cr | 213.2Cr |
China | 166.14Cr | 145.28Cr | 153.97Cr | 166.04Cr | 195.1Cr |
Executive Committee: Eli Lilly and Company
| Manager | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 58 | 01/01/2017 |
Lucas Montarce
DFI | Director of Finance/CFO | 49 | 09/09/2024 |
| Chief Tech/Sci/R&D Officer | 52 | - | |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/2023 |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | 51 | 17/05/2021 |
Composition of the Board of Directors: Eli Lilly and Company
| Director | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 65 | 01/01/2005 |
Ralph Alvarez
BRD | Director/Board Member | 69 | 01/04/2009 |
| Director/Board Member | 54 | 12/12/2011 | |
David Ricks
CHM | Chairman | 58 | 01/06/2017 |
William Kaelin
BRD | Director/Board Member | 68 | 04/06/2012 |
Juan Luciano
BRD | Director/Board Member | 64 | 01/02/2016 |
Jamere Jackson
BRD | Director/Board Member | 56 | 01/10/2016 |
| Director/Board Member | 65 | 25/01/2021 | |
Kimberly Johnson
BRD | Director/Board Member | 53 | 16/02/2021 |
| Director/Board Member | 63 | 15/05/2022 |
Holdings: Eli Lilly and Company
| Name | Equities | % | Valuation |
|---|---|---|---|
AKTIS ONCOLOGY, INC. 12.08% | 63,44,114 | 12.08% | 128 M $ |
| 60,97,792 | 1.35% | 50 M $ | |
PROQR THERAPEUTICS N.V. 16.06% | 1,68,95,100 | 16.06% | 27 M $ |
| 40,00,000 | 6.83% | 23 M $ | |
PEIJIA MEDICAL LIMITED 2.97% | 1,99,52,740 | 2.97% | 17 M $ |
| 16,17,500 | 0.28% | 13 M $ |
Company details: Eli Lilly and Company
Group companies: Eli Lilly and Company
| Name | Category and Sector |
|---|---|
Lilly Asia Ventures Fund II LP
 Lilly Asia Ventures Fund II LP Investment ManagersFinance Acts as Venture Capital Fund |
Investment Managers
|
ELI Lilly & Company (India) Pvt Ltd.
 ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products |
Pharmaceuticals: Major
|
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
 Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and sells pharmaceutical products |
Pharmaceuticals: Major
|
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and sells pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.04% | -4.28% | +5.22% | +206.70% | 90TCr | |
| -2.56% | -1.87% | +44.69% | +53.59% | 59TCr | |
| -1.47% | +3.09% | +9.49% | +49.17% | 42TCr | |
| -2.03% | -4.77% | +15.55% | +28.35% | 37TCr | |
| -2.08% | -2.92% | +22.46% | +37.00% | 31TCr | |
| -2.24% | -3.84% | +25.60% | +57.30% | 31TCr | |
| -2.39% | -2.87% | +24.35% | +4.30% | 30TCr | |
| -3.30% | -3.42% | +15.72% | +55.82% | 20TCr | |
| -2.28% | +0.70% | +25.42% | +78.50% | 18TCr | |
| +1.30% | +4.30% | -59.65% | -50.72% | 17TCr | |
| Average | -1.90% | -0.28% | +12.89% | +52.00% | 37.54TCr | |
| Weighted average by Cap. | -2.03% | -0.62% | +16.20% | +78.84% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock
- Company Eli Lilly and Company
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition